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ings is unknown at present, some centers currently prefer to transplant these patients with PBSCs that have been depleted of potentially contaminating tumor cells. One To evaluate the feasibility and efficacy of CD34 ؉ cell immunoselection from routine peripheral blood stem possible method of reducing tumor cell contamination of the PBSC preparations is the positive selection of CD34 ϩ cell (PBSC) harvests in very small children a prospective study was performed in 15 children with advanced hematopoietic progenitor cells. 3 Initial trials of autografts with CD34
ϩ PBSCs have mainly been performed in adult neuroblastoma weighing 20 kg or less. Products of two consecutive leukaphereses carried out on a COBE Specpatients [4] [5] [6] and, outside of our team, 7 and so thus far there have been no reports of studies performed in small children. tra separator after G-CSF alone mobilization were pooled for immunoselection on Ceprate column. The
The principal reasons for the restriction in the use of this technique in children with low body mass are PBSC collecmedian number of CD34 ؉ cells and total CFU-GM collected were respectively 5.9 ؋ 10 6 /kg (range 2.3-23.4) tion-associated difficulties (venous access, flow rate, metabolic and hemodynamic problems). In particular, when and 126.9 ؋ 10 4 /kg (range 52.9-559.9). After separation the median number of CD34 ؉ cells in the adsorbed fraclarge-scale collection is planned, which may require the processing of a considerable number of blood volumes, the tion was 2.6 ؋ 10 6 /kg (range 1-9.8) with a median purity of 54% (range 21-82) and a median of 95.7-fold safety of the procedure is of special importance.
8-13
We report the results of a prospective study designed to (range 35-250) enrichment. Thirteen patients underwent autografts with CD34 ؉ PBSCs after a busuldetermine whether sufficient numbers of CD34 ϩ cells can be obtained to provide reliable post-graft hematopoietic fan 600 mg/m 2 ؉ melphalan 180 mg/m 2 preparative regimen. The median number of days to achieve an reconstitution in very small children, after positive immunoselection of routinely collected leukaphereses products. absolute granulocyte count of 0.5 ؋ 10 9 /l and a platelet count of 20 ؋ 10 9 /l were respectively, 12 (range 10-24) We have investigated the feasibility and efficacy of this technique using the avidin-immunoaffinity column device and 35 (range 25-43). The median number of platelet transfusions was nine (range 2-15). We conclude that (Ceprate Stem Cell Concentrator; CellPro, Bothell, WA, USA) in 15 children with advanced neuroblastoma. These safe and effective immunoselection and transplantation of CD34
؉ PBSC can be accomplished in children with patients may theoretically benefit from the isolation of CD34 ϩ hematopoietic progenitors, since the target CD34 low body mass. Keywords: CD34 PBSC transplantation; children; neuroantigen is not expressed on neuroblastoma cells 14,15 and a reduction in the tumor contamination of the graft may be blastoma presumed. We report clinical and biological data concerning the mobilization, collection, immunoselection and transplantation of CD34 ϩ PBSCs in these young subjects. Peripheral blood stem cells (PBSCs) are increasingly used for autografting after high-dose chemotherapy. However, it has recently been shown that in patients with breast cancer, Patients and methods myeloma, neuroblastoma and other solid tumors, circulating malignant clonogenic cells can contaminate PBSC harPatients vests. 1, 2 Although the biological significance of these findFifteen children who were candidates for high-dose chemotherapy with stem cell rescue because of advanced neuro-performed in the Unité Bioclinique de Prélèvement et de procedure being of importance. Acid-citrate-dextrose (ACD) was used as an anti-coagulant. To prevent hypocalTraitement des Cellules Souches Hématopoïéques of Clermont-Ferrand, whereas pre-mobilization treatments and cemia calcium gluconate was systematically administered before leukapheresis began and during collection. In most transplantations were carried out in the original hospitals. The risks of the procedure were explained in detail and patients, a single lumen central line (Broviac catheter, 1.0 mm lumen; Laboratoires Bard, Trappes, France) was informed consent was obtained from all patients' parents. The protocol was approved by the Comité de Protection routinely inserted at the initial diagnosis and it was used for the withdrawal or return of processed blood during leudes Personnes dans la Recherche Bio-Médicale pour la région Auvergne.
kapheresis. A temporary femoral catheter was used if no central line had previously been inserted and/or if it was Assessment of disease status at diagnosis and at the end of pre-mobilization treatments were within the minimum impossible to ensure adequate blood flow with peripheral veins. After the start of the procedure, the blood flow rate INSS criteria. 16 Evaluation of bone and marrow disease was performed with meta-iodobenzylguanidine (MIBG) scans was gradually increased to the maximum rate achievable. The rate of blood withdrawal that was maintained for the Ϯ technetium-99 scans. Bone marrow aspirates were performed at 10 sites (iliac anterior and posterior right and longest duration per leukapheresis was considered the 'average' rate. Complications related to leukapheresis were left: eight sites; sternal: two sites); the number of core biopsies was two. Inclusion criteria were: (1) the diagnosis assessed by clinical examination and full blood count (1 h post-leukapheresis). of neuroblastoma established by standard histologic and immunocytologic analysis and/or demonstration of tumor cells in the bone marrow of patients with elevated urinary Selection of CD34 ϩ cells catecholamines; (2) stage IV neuroblastoma with bone marrow involvement; (3) chemotherapy and surgery treatTwo consecutive harvests were used for immunoselection; one was directly frozen as a backup of unseparated PBSCs. ment according to Société Française d'Oncologie Pédia-trique (SFOP) protocol NB92; and (4) medullary complete
The decision as to whether to keep the harvest for pooling and immunoselection or immediate freezing was made on remission prior to mobilization. Patients with progressive disease, major organ dysfunction or Karnofsky perform-(1) a daily basis depending on CD34 ϩ cell numbers in this product and (2) mobilization kinetics data. The first of the ance status 17 less than 70% were excluded. two harvests to be immunoselected was stored at 4°C for 24 h and then pooled with the second. Immunoselection Hematopoietic progenitor mobilization procedure was carried out following guidelines given by the column manufacturer. The cell suspension was incuHematopoietic progenitor mobilization has been described elsewhere. 18 Briefly, granulocyte colony-stimulating factor bated with biotinylated 12.8 MoAb, 20 washed and filtered through a computer-driven avidin-immunoaffinity column (G-CSF; Filgrastim, Amgen, Thousand Oaks, CA, USA) alone was administrated at a dose of 10 g/kg/once daily device (Ceprate Stem Cell Concentrator; CellPro, Bothell, WA, USA). The CD34 ϩ cells were released from the avidin by subcutaneous injection. The mobilization started at least 21 days after the end of the last chemotherapy course. In beads by mechanical agitation. Aliquots were taken from the sample installed on the column, main column after eluall patients the kinetics of mobilization were monitored daily using full blood counts, reticulocyte subpopulation tion (a sample of total contents: cells ϩ beads was taken with a syringe) and CD34 Ϫ and CD34 ϩ fractions for flow counts and peripheral blood progenitor cell levels (CD34 ϩ cells, granulocyte-macrophage colony-forming units (CFUcytometric analysis and progenitor cell clonogenic assays. The selected CD34 ϩ cell suspension was centrifuged, re-GM), erythroid burst-forming units (BFU-E). Reticulocyte counting and high fluorescence reticulocyte (HFR) values suspended in 4.5-ml final volume aliquots of PBS medium with 7.5% dimethylsulfoxide and 4% HSA and stored at were obtained using a Sysmex R-1000 (Merck, Clevenot, France) (TOA Medical Electronics Co, Kobe, Japan), a Ϫ196°C to be reinfused later into patients. fully automated flow cytometric reticulocyte counter. 19 Flow cytometry PBSC collection CD34 ϩ cells were evaluated by direct immunofluorescence on whole blood samples, leukapheresis products and immuThe timing for the collection was based on the daily evaluation of blood CD34 ϩ cell mobilization kinetics. Cells were noselection fractions after incubation with CD34-PE conjugated MoAb (8G12; HPCA-2; Becton Dickinson, San Jose, collected in the pediatric environment using a COBE Spectra continuous-flow blood-cell separator (COBE, Lake-CA, USA). Analyses were carried out using a Cytoron cytometer (Cytoron Absolute, Ortho Diagnostic System, wood, CO, USA). The procedures were performed under manual control. Procedures were carried out daily for 3 Roissy, France). Fifty thousand events were acquired on the dot plot, forward light scatter vs side (90°) light scatter, days. Each procedure took place 12 h after the preceding dose of G-CSF. In general, for patients with blood volume which allows the identification of the major leukocyte subsets. After acquisition, two live gates were drawn on the Ͻ1 l and/or a hemoglobin level Ͻ100 g/l, the extracorporeal line was primed with 150 ml of irradiated, CMV dot plot of both light scatters, one (R 1 ) containing the mononuclear cells (lymphocytes and monocytes), the other negative, red blood cells (hematocrit 55-60%). However, the decision to prime or not was made case by case, the (R 2 ) containing the total nucleated cells. For leukapheresis products and all immunoselection fractions the absolute child's general condition and the anticipated duration of value of CD34 ϩ cells was calculated by the multiplication Evaluation of neuroblastoma cells of the percentage of CD34 ϩ cells in the total nucleated cell To determine residual neuroblastoma cell contamination, gate R 2 and the total nucleated cell count per ml. The absolthe leukapheresis products and selected CD34 ϩ cell fracute value of CD34 ϩ cells in blood samples was calculated tions were examined microscopically and using the immuby the multiplication of the percentage of CD34 ϩ cells in nocytologic technique with UJ-13-A, GD2, CD45 antibody the mononuclear cell gate R 1 and the absolute number of (sensitivity: 1 tumor cell within 10 5 total cells). 21 mononuclear cells per ml.
High-dose chemotherapy and CD34 ϩ PBSC transplantation Clonogenic assay
High-dose chemotherapy with cumulative doses of 600 mg/m 2 busulfan and 180 mg/m 2 melphalan was adminThe frequency of clonogenic cells in each fraction was istered from day Ϫ 6 to day Ϫ2. Positively selected CD34 ϩ evaluated by plating in triplicate in Iscove's modified DulPBSCs were reinfused 24 h after the end of high-dose therbecco's medium (IMDM) (Gibco, Glasgow, UK) containapy. All patients received G-CSF (10 g/kg) by intraing 0.95% methylcellulose (Fluka, Buch, Switzerland), venous injection given from day 1 after infusion of CD34 ϩ 30% fetal calf serum (FCS), 1% bovine serum albumin cells and continued every day until neutrophil recovery (BSA), 100 mmol/l ␤ 2 -mercaptoethanol, 2 mmol/l l-gluta-(absolute neutrophil count ANC Ͼ1 ϫ 10 9 /l for 2 consecumine, penicillin-streptomycin (Sigma, St Louis, MO, USA), tive days). Supportive care during the aplastic period is rh-Epo (Boehringer-Mannheim, Mannheim, Germany) at described elsewhere. 8 Briefly, patients were maintained in 3 UI/ml, rh-IL-3 at 100 UI/ml and rh-GM-CSF at a laminar air flow room after myeloablative therapy until 200 UI/ml (Tebu, Paris, France) in 35 mm Petri dishes their neutrophil levels reached 0.5 ϫ 10 9 /l. Patients with (Dutscher, Brumoth, France). Positively selected CD34 ϩ ANC Ͻ0.5 ϫ 10 9 /l and a temperature greater than 38°C cells were plated at a concentration of 1.25 ϫ 10 3 cells/ml received intravenous ceftazidime and amikacin Ϯ vancoand the other fractions at 4 ϫ 10 4 cells/ml. Harvest fracmycin. Amphotericin B was added for documented fungal tions and positively selected CD34 ϩ cell fractions were infection or if fever was present 48 h after antibiotics had plated directly whereas mononuclear cells from blood been instituted. The blood transfusion protocol was as folsamples were obtained by density gradient centrifugation.
lows: phenotyped packed red cells were given when hemoMain column fraction was plated without beads removed.
globin level fell below 80 g/l and a single-donor platelet Granulocyte colony-forming units (CFU-G), macrophage transfusion when platelets fell below 20 ϫ 10 9 /l with fever colony-forming units (CFU-M), CFU-GM, BFU-E and and/or bleeding. All blood products were irradiated. mixed myeloid-erythroid colony-forming units (CFU-Mix) were counted under an inverted microscope after 14 days of incubation under fully humidified conditions at 37°C in Statistical analysis a 5% CO 2 atmosphere. Progenitors that gave rise to 50 or more cells were scored as non-erythroid colonies and ident-
The clinical and laboratory data of patients were analyzed ified by their characteristic colony morphology. BFU-E according to standard statistical methods using a panel data consisting of three or more clusters were identified by their analysis with commercially available computer program orange/red coloration. Presence of 50 or more non-(Limdep; Econometric software Inc, Bellport, NY, USA). erythroid cells in BFU-E defined CFU-Mix. The morphology of colonies was confirmed on May-GrunwaldGiemsa, myeloperoxidase, butyrate esterase stained smears.
Results The notation CFU-GM is commonly used in graft practice but this cellular colony type is not really defined. In this
Patients and pre-leukapheresis treatment study we have included in total CFU-GM (CFU-GM T ): CFU-G, CFU-M, CFU-GM and CFU-Mix; total BFU-E Details concerning the patients are listed in Table 1 . The patients include 12 boys and three girls who weighed 20 kg (BFU-ET T ) enclosed BFU-E and CFU-Mix. The CFU-GM T and BFU-E T can be considered to be equivalent to usual or less at the time they underwent leukapheresis collection of PBSC. The median age of the patients was 4 years (range quality control parameters used by most authors. The number of progenitors per ml blood was calculated by dividing 1.5-8 years) and median weight and blood volume were respectively 15 kg (range 10-20 kg) and 1.4 l (range 0.8-the absolute number of mononuclear cells in 1 ml of whole blood by the number of mononuclear cells plated to obtain 1.8 l). All patients had advanced neuroblastoma with marrow involvement at diagnosis, associated with bone (13 one colony. For leukapheresis products which were plated without any separation procedure the number of colonies patients) and/or liver metastases (two patients). Pre-mobilization treatment modalities consisted of four sequences of observed represented the number of progenitors in this product. Clonogenicity was calculated from absolute progenialternating chemotherapy, either cyclophosphamide ϩ doxorubicin ϩ etoposide and etoposide ϩ cisplatin or etotor counts identified by clonogenic assays and absolute CD34 ϩ cell counts plated. The numbers of progenitor cells poside ϩ cisplatin and cyclophosphamide ϩ etoposide Ϯ two sequences of carboplatin ϩ etoposide. All chemodeclared as 'infused into the patients' correspond to the numbers of progenitor cells found in the evaluation carried therapy courses were followed by G-CSF administration. All patients had undergone surgery for primary tumor out immediately before freezing. 6 ) in these two leukaphereses. These procedures were second complete remission (CR 2 ) after bone marrow relapse. He had not received more pre-mobilization treatcarried out largely without difficulty. No signs of complications due to citrate toxicity were encountered. There were ment than others, but had had a significantly longer interval from diagnosis to PBSC collection. no clinically significant effects on peripheral blood counts except on platelet counts which diminished following each procedure with a median 35.6% (range 10.9-54.2%) Hematopoietic progenitor mobilization decrease. However, none of the patients had profound thrombocytopenia and no procedure-related transfusions Priming started 21 to 54 days (median 26 days) after the end of the last chemotherapy course. G-CSF priming led were needed throughout the study. to a median 17-fold (range 3-60) enrichment of circulating CD34 ϩ cells, 29-fold (range 8-171) and 37-fold (range 7-Positive selection of PB CD34 ϩ cells 189) enrichment of circulating CFU-GM T and BFU-E T , respectively. Blood count and progenitor cell numbers in Median neutrophil and monocyte 'contamination' of harvest products were: 11.5% (range 1-66%) and 31.5% peripheral blood at the time of the first of two leukaphereses used for immunoselection were: WBC 36.3 ϫ 10 9 /l (range 16-67%) respectively, with median hematocrit 1.9% (range 0.1-3.2%) and median platelets number 423.5 ϫ (range 11.1-64.7 ϫ 10 9 /l); lymphocytes 1.7 ϫ 10 9 /l (range 0.8-4.8 ϫ 10 9 /l), HFR 5.5 ϫ 10 9 /l (range 1.5-23 ϫ 10 9 /l), 10 9 /l (range 192-1000 ϫ 10 9 /l). In the harvest fraction the median number of total nucleated cells (TNC) was 13.2 ϫ CD34 ϩ cells 27 ϫ 10 6 /l (range 6-112 ϫ 10 6 /l), CFU-GM T 6.6 ϫ 10 6 /l (range 0-37.6 ϫ 10 6 /l). G-CSF injections were 10 8 /kg with a median 0.6% of CD34 ϩ cells. After column separation CD34 ϩ cells were enriched 95.7-fold (n ϭ 15; well tolerated and there were no complications related to mobilization.
range 35-250) with a purity of 54%. Data from clonogenic assays of each fraction are available for the first 12 patients with detailed quantitative evaluation of colonies performed PBCD34 ϩ cell collection in the first nine patients (Table 3 ). To evaluate step by step the efficiency of the immunoselection procedure, progenitor Leukaphereses started after the third or fourth G-CSF dose. Three leukaphereses were performed for each patient. Two cell recovery was calculated on two levels: (1) 'Harvest/Stem' corresponded to overall cell recovery from consecutive harvests, the first and the second (10 patients) or the second and the third (five patients) were used for the start of processing leukapheresis bags (washing, incubation, washing, filtration through an avidin column); immunoselection. One was directly frozen as a backup. The data of two collection procedures from which the products (2) 'Sample/Stem' recovery corresponded to cell recovery during filtration through an avidin column ( Table 4 ). The were used for immunoselection are shown in Table 2 . In 10 of 15 patients peripheral venous access was used during washing and incubation steps induced loss of 14% CD34 ϩ cells (range 1-42%) and resulted in decrease in CFU-GM T collection, with a central catheter inserted routinely at diagnosis (nine patients) or with a temporary femoral catheter and BFU-E T of 42% (n ϭ 12; range 2-74%) and 33% (n ϭ 12; range 0-78%) in identical culture conditions. No cor-(one patient). In four patients a temporary femoral catheter access was used with a central catheter. One patient had relation was found between 'contaminating' cell concentration (neutrophils, monocytes, platelets) before or after two femoral catheters for both access and return. The median CD34 ϩ cell number per patient obtained in these pre-column manipulations and progenitor recovery or purity of stem fraction. No correlation was found between two harvests was 5.9 ϫ 10 6 /kg. Both leukapheresis procedures were similar in terms of progenitor cell harvest.
initial cell concentration in sample installed on column (TNC, CD34 ϩ cell, CFU-GM T , BFU-E T ) and progenitor The median numbers of CD34 ϩ cells collected per patient kg and per one patient's blood volume processed were 1.2 recovery or purity in stem fraction. ACD ϭ acid/citrate-dextrose; MNC ϭ mononuclear cells; NE ϭ nonevaluable; CFU-GM total ϭ granulocyte-macrophage colony-forming units defined as CFU-G ϩ CFU-M ϩ CFU-GM ϩ CFU-Mix; BFU-E total ϭ erythroid burst-forming units defined as BFU-E ϩ CFU-Mix. a Number of cells in pooled product.
PB CD34
؉ cell transplantation in children M Berger et al 196 TNC ϭ total nucleated cells; CFU-GM total granulocyte-macrophage colony-forming units defined as CFU-G ϩ CFU-M ϩ CFU-GM ϩ CFU-Mix; BFU-E total ϭ erythroid burst-forming units defined as BFU-E ϩ CFU-Mix; CFU-GM ϭ granulocyte-macrophage colony-forming units; CFU-G ϭ granulocyte colony-forming units; CFU-M ϭ macrophage colony-forming units; CFU-Mix; BFU-E ϭ erythroid burst-forming units. up of all transplanted patients continues. Six patients had more than 52 weeks survival without relapse and Engraftment characteristics chemo/radiotherapy treatment at the time when the data were analyzed and had a stable and normal hematopoiesis. Thirteen patients are evaluable for hematological recovery after PB CD34 ϩ cell reinfusion. Two patients (Nos 9 and 13) relapsed before starting conditioning regimens and have Discussion not been transplanted. One patient (No. 6) received only half of the cryopreserved graft (4.7 ϫ 10 6 CD34 ϩ cells/kg) as the graft was very rich (9 ϫ 10 6 CD34 ϩ cells/kg). No The principal criteria for the evaluation of the feasibility of using CD34 ϩ PBSC transplantation in small children are: premedication was administered before infusion of selected (1) the mobilization and collection of a sufficiently large technique is equivalent to that of Takaue et al 9 while our theoretical overall procedural toxicity is reduced. number of progenitor cells as about 50% of CD34 ϩ cells collected are presumed lost during the selection pro-CD34 ϩ cell immunoselection from G-CSF-alone primed PBSCs results in sufficient numbers of progenitor cells per cedure; [4] [5] [6] [7] 15, 22 (2) the confirmation of the efficacy of selection technique (recovery rate, purity) in the light of differpatient kg to allow transplantation. The overall recovery of CD34 ϩ cells (45.3%) was in accordance with previously ent characteristics of the installed samples (overall cell concentration) when compared to adults; and (3) the sucreported data in adults. [4] [5] [6] We could not undertake a step by step evaluation of our procedure compared to others as cessful short-and long-term hematopoietic recovery.
In this study we confirmed that G-CSF-alone mobilizcertain data such as 'installed on column' fraction or main column fraction contents are not given in most reports. ation is convenient for immunoselection in small children, as well as in adults, 5, 6 since collection times can be preMoreover, in terms of clonogenic potential of CD34 ϩ cells in different fractions it is difficult to compare the selection cisely planned to coincide with the progenitor increase phase for maximal collection of these cells. During mobilizefficiency from one team to another because of the lack of standardization of culture techniques. Published results are ation two observations merit consideration: (1) a strong correlation between HFR and blood CD34 ϩ cell levels (n usually imprecise as to which subcolonies are included in the CFU-GM T and BFU-E T figures. In this study CFU-Mix ϭ 15, r ϭ 0.7, P ϭ 0.00005). This easy-to-evaluate parameter may be useful as an early indicator of the circulating were included in both CFU-GM T and BFU-E T as these colonies were considered to contain both erythroid and granprogenitor increase during mobilization; (2) best results in terms of enrichment in circulating progenitor cells were ulo-macrophagic components. CFU-Mix represented р7% of CFU-GM T and р8% of BFU-E T . Analysis showed that obtained in patients who had not had any anthracycline administration prior to mobilization. To avoid the problems the exclusion of CFU-Mix colonies from the total count of more mature colonies did not modify the results. In our linked to large-scale collection of PBSCs in the smallest of patients we used a COBE Spectra separator model which study the clonogenic potential of CD34 ϩ cells in stem fraction compared to CD34 ϩ cells in harvest fraction was conis well adapted for use with children as it offers the possibility of low blood flow rates without loss of collection sistently diminished in identical culture conditions. Not only was a reduction in clonogenicity noted between the efficiency, reduced use of citrate anticoagulant and easy priming of extracorporeal line with blood before the pro-CD34 ϩ cells in the installed sample and the stem fraction but also pre-column cell manipulation alone lowered the cedure. In terms of procedure safety: in only six patients was a temporary femoral catheter specifically installed for proliferation capacity of these cells (when still cultured under identical conditions). collection; in nine children we used previously inserted central lines and peripheral veins for access/return. No proWe confirm the successful hematopoietic reconstitution after myeloablative conditioning followed by PB CD34 ϩ cedure-related complications were observed. In terms of collection efficiency our results show that the processing cell transplantation. However, median time to platelets Ͼ20 ϫ 10 9 /l was 35 days which is longer than that in historical of a median 4.7 blood volumes per patient during two leukapheresis procedures was sufficient to achieve, after groups after unselected PBSC grafts. 18 Compared with neutrophils, the time variation to normalization of platelet immunoselection, the threshold dose of 1 ϫ 10 6 CD34 ϩ cells/kg for all patients. Moreover, in 12 of 15 patients counts was more pronounced. In our study, hematopoietic recovery times were not directly linked to selected CD34 ϩ enough PBSCs to plan immunoselection (more than 2.5 ϫ 10 6 CD34 ϩ cells/kg in harvest product) were obtained with cell, CFU-GM T or BFU-E T numbers infused. However, longest platelet recoveries were observed in patients with р3 blood volumes processed (data not shown). The median number of blood volumes that had to be processed to obtain the smallest grafts. Platelet recovery appears to be the limiting cell lineage as far as this technique is concerned. Three 2.5 ϫ 10 6 CD34 ϩ cells/kg was 2 (range 0.5-4.5). This observation introduces the possibility of reducing the numpatients had serious late infections, something which is not normally observed with non-manipulated PBSC transplanber and/or duration of collection procedures while maintaining efficacy.
tation.
Once the feasibility of CD34 ϩ immunoselection from Outside of our team the most clinical information on the use of PBSCs in the smallest of children has been provided PBSCs in small children has been demonstrated, its utility in neuroblastoma treatment requires confirmation. In this by Takaue et al. 9 They confirmed that it is possible to collect a large number of PBSCs for transplantation in the study we were not able to demonstrate the purge effect using an immunocytologic technique. The use of more smallest of children. However, the systematic use of a radial arterial catheter (20-24 gauge), high ratios of ACD (6.7) sensitive methods of detecting neuroblastoma cells, eg reverse transcriptase-polymerase chain reaction for tyrosine and continuous calcium gluconate infusions increases the complexity of the procedure. It is difficult to compare the hydroxylase mRNA 23 will be helpful in demonstrating an eventual purge. The demonstration that the use of tumor collection efficiency in our study with the data from Takaue et al 9 because of the different methods of PBSC mobilizcell-depleted graft transplantations has a beneficial effect on patient outcome requires a prospective randomized ation (only two patients had G-CSF-alone priming) and presumed differences in circulating PBSC levels at the time study measuring relapse rate and/or survival. In summary, we have shown that immunoselection of of leukapheresis. However, the calculated minimum volume of blood that had to be processed to collect 10 ϫ 10 4
CD34
ϩ cells from peripheral blood after short-term mobilization by G-CSF alone is feasible in the smallest of chil-CFU-GM/kg is similar in Takaue et al's and in our study. It would appear that the overall procedural efficacy of our dren. Immunoselection results in terms of purity, recovery 
